Lockheed Martin and Johnson & Johnson released their latest earnings reports before opening bell this morning. Lockheed Margin reported adjusted earnings of $3.25 per share on $13.75 billion in revenue. Analysts had been expecting the defense contractor and airplane manufacturer to report $3.05 per share in earnings and $13.03 billion in revenue. In last year’s fourth quarter, the company reported $11.52 billion in revenue.
Johnson & Johnson reported $1.58 per share in adjusted earnings, marking a 9.7% year over year increase, and $18.11 billion in revenue. Analysts had been expecting the consumer products company to report $1.56 per share in adjusted earnings and $18.26 billion in revenue. In the previous year’s fourth quarter, the company posted $17.81 billion in revenue.
Many value investors have given up on their strategy over the last 15 years amid concerns that value investing no longer worked. However, some made small adjustments to their strategy but remained value investors to the core. Now all of the value investors who held fast to their investment philosophy are being rewarded as value Read More
Lockheed Martin said aeronautics sales rose to $5.41 billion from $4.38 billion in the same quarter a year ago. The company’s GAAP earnings rose to $3.35 per share from $3.01 per share in the year-ago quarter.
Lockheed Martin expects revenue for this year to be between $49.4 billion and $50.6 billion, compared to the consensus of $49.6 billion. It expects earnings to fall between $12.25 and $12.55 per share, compared to the consensus of $12.88 per share.
Shares of Lockheed Martin declined by as much as 1.47% to $253.70 in premarket trading this morning.
Johnson & Johnson’s net earnings rose to $1.38 per share from $1.15 per share in the fourth quarter of 2015. Domestic sales rose 2.6% year over year, while international sales ticked upward by 0.6% on the back of currency headwinds amounting to 1.3%. Consumer sales rose 3.4% to $3.4 billion in the fourth quarter, while Pharmaceutical sales rose 2.1% to $8.2 billion. Medical Devices sales increased -.2% to $6.4 billion.
The company’s 2017 full-year sales outlook stands between $74.1 billion and $74.8 billion, marking between 4% and 5% operational growth. Johnson & Johnson expects adjusted earnings to be between $6.93 and $7.08 per share for the full year.
Johnson & Johnson shares ticked downward by as much as 1.67% to $112.01 in premarket trades.